By identifying common gene variants that raise the risk of an aggressive form of the childhood cancer neuroblastoma, researchers may assist diagnostic efforts.

A CHOP oncologist co-led an international study showing that an abnormal fused gene drives children’s brain tumors by using three different biological mechanisms. 

CHOP researchers have identified a powerful new drug with “unparalleled” strength against refractory types of neuroblastoma.

Proton therapy for a 3-year-old with neuroblastoma compared to X-ray therapy allowed a 100-fold reduction in radiation dose to the liver, lungs, and heart.